Omega-3: Why DHA and EPA Are Not the Same Supplement

Docosahexaenoic acid (DHA) is a 22-carbon polyunsaturated fatty acid, and it is the single most abundant fatty acid in the human brain. It comprises roughly 40% of the polyunsaturated fatty acids in neuronal membranes and is concentrated at the synaptic terminals and retinal photoreceptors — the two sites in your body where signal transduction speed matters most.

DHA doesn't sit passively in the membrane. Its extreme unsaturation — six double bonds along the carbon chain — creates kinks in the molecule that prevent tight packing. When DHA is incorporated into the phospholipid bilayer, it increases membrane fluidity. This fluidity is not a metaphor. It's a measurable biophysical property that directly determines how quickly receptors can move laterally across the membrane surface, how efficiently ion channels open and close, and how rapidly vesicles fuse during neurotransmitter release.

A neuron with adequate DHA in its membranes transmits signals faster and more reliably than one with depleted DHA. Studies in DHA-deficient animal models show impaired long-term potentiation (the cellular mechanism of learning), reduced hippocampal neurogenesis, and measurable cognitive deficits that reverse when DHA is restored.

The omega-3 literature is enormous and, at first glance, contradictory. The pattern becomes clear when you match the specific molecule to the specific outcome.

Depression trials consistently favor EPA-dominant formulations over DHA-dominant ones — aligning with the SPM-mediated neuroinflammation resolution hypothesis. Cognitive trials favor DHA, consistent with its structural role in neuronal membranes.

The VITAL trial (2019), one of the largest omega-3 RCTs ever conducted, found no significant reduction in major cardiovascular events from 840 mg combined EPA/DHA daily — but subgroup analysis revealed a significant 28% reduction in heart attack specifically, and stronger effects in participants with low baseline fish consumption. The REDUCE-IT trial (2018) used 4 grams of pure EPA daily and found a 25% relative risk reduction in cardiovascular events — a dramatically larger effect than any mixed EPA/DHA study had produced.

The pattern is consistent: match the molecule to the outcome and the effects are clear. Lump them together at generic doses and the signal dilutes.

Triglyceride-form fish oil has roughly 70% greater bioavailability than ethyl ester form. Re-esterified triglycerides (rTG) are the premium format — molecularly distilled, concentrated, and in the natural triglyceride configuration. Ethyl esters are cheaper but require additional enzymatic processing in your gut.

Algal oil is the only vegan source of preformed DHA. Flaxseed and chia provide alpha-linolenic acid (ALA), an 18-carbon omega-3 that requires conversion to EPA and DHA — a process that operates at roughly 5 to 10% efficiency in humans. ALA is not a reliable substitute for direct EPA/DHA supplementation.

Quality markers to look for: third-party testing for oxidation (TOTOX value), heavy metal content (mercury, PCBs), and actual EPA/DHA content per serving rather than total fish oil volume. The difference between what's on the front of the label and what's on the back is often substantial.

Omega-3 is infrastructure, not intervention. It doesn't produce a feeling. It maintains the membrane fluidity that makes your neurons fast, and it builds the molecular machinery that resolves the inflammation your lifestyle creates. The question isn't whether to supplement — it's whether you're using the right molecule for the right goal, and whether your omega-6 intake is undermining the investment.

For people moving between countries, eating inconsistently, and generating chronic low-grade inflammation through travel stress and schedule variability — omega-3 at adequate doses is one of the least negotiable foundations available.

1. Swanson D, et al. "Omega-3 fatty acids EPA and DHA: health benefits throughout life." Advances in Nutrition, 2012.
2. Bhatt DL, et al. "Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia." REDUCE-IT trial. New England Journal of Medicine, 2019.
3. Manson JE, et al. "Marine n-3 fatty acids and prevention of cardiovascular disease and cancer." VITAL trial. New England Journal of Medicine, 2019.
4. Serhan CN. "Pro-resolving lipid mediators are leads for resolution physiology." Nature, 2014.
5. Sublette ME, et al. "Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression." Journal of Clinical Psychiatry, 2011.